Elite Pharmaceuticals secures FDA approval for generic Sabril
Elite Pharmaceuticals, a specialty pharmaceutical company developing niche generic products, has received clearance from the Food and Drug Administration for a generic version of Sabril (vigabatrin) 500 mg powder for solution packet.
[Read more: Elite, Prasco launch loxapine capsules]
Vigabatrin is an antiepileptic drug indicated for refractory complex partial seizures and used as an adjunctive therapy in patients who have inadequately responded to several alternative treatments.
[Read more: Zydus obtains FDA nod for generic Sabril]
Lannett has an exclusive license to market and distribute the product in the United States and territories. Elite will exclusively manufacture and package the product for sale for an agreed-upon transfer price. The companies will share in product net profits, according to Elite.